You are here: Industry Insights > Personalized Medicine

News List

Ethical and Regulatory Considerations in Personalized Medicine Saher Haider
April 07, 2025
Personalized medicine is revolutionizing healthcare by tailoring medical treatments to individual genetic profiles, lifestyles, and environmental factors.
Microbiome Impact on Drug Response and Personalized Medicine Nurah Ekhlaque
February 18, 2025
The gut microbiome impacts drug response and disease management. It affects drug metabolism, efficacy, and toxicity, and is crucial for personalized medicine.
Advancements in Personalized Medicine Research Saher Haider
February 05, 2024
Personalized Medicine, also known as Precision Medicine, Individualized Medicine.
Pharma Sources Insight January 2024: Pharmaceutical Industry in 2024 - Flexible Production, Innovative Drugs and Personalized Medicine Pharma Sources Insight
January 15, 2024
Pharmaceutical Industry Outlook in 2024.
Personalized Medicine: A New Era in Healthcare David Orchard-Webb
January 02, 2024
Personalized medicine, also known as precision or individualized medicine, is a rapidly evolving field where medical decisions are tailored to individual patients based on their genetic and genomic data.
Pharma and Health from Ingredients to Pills: 3D Printing for Personalized Medicine Lin Zhang
June 23, 2020
Personalized medicines are becoming more popular as they enable the use of patient’s unique characteristics which could play a vital role in the treatment of life-threatening diseases.
With personalized medicine, a shelved cancer drug could get another shot WorldPharmaNews
February 09, 2022
A study by Virginia Commonwealth University Massey Cancer Center researchers published in today's print edition of Molecular Cancer Therapeutics shows that triplatin is effective against triple negative breast cancer...
Using personalized medicine to avoid resistance to leukemia treatment worldpharmanews
May 11, 2021
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20.
n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases americanpharmaceuticalreview
April 07, 2021
n-Lorem Foundation announced a new partnership with Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases.
Genomenon Commended by Frost & Sullivan for Advancing Clinical Genomics Interpretation and Personalized Medicine with Its Mastermind Platform prnasia
February 12, 2020
Based on its recent analysis of the global clinical genomics interpretation market, Frost & Sullivan recognizes Genomenon, Inc. with the 2020 Global Company of the Year Award.